Published on
April 17, 2026
- 19:00 GMT
Angiex Reports AACR In Vivo Data Supporting AGX101 in Combination With Immune Checkpoint Inhibitors for Solid Tumors
Preclinical in vivo data suggest AGX101 may enhance checkpoint inhibitor activity through selective targeting of tumor vasculature CAMBRIDGE, MA, UNITED STATES, April 17, 2026 /EINPresswire.com/ -- Angiex Inc., a developer of Nuclear-Delivered Antibody- …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
